--- title: "Regenxbio | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 108.02 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295097600.md" datetime: "2026-08-06T11:16:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295097600.md) - [en](https://longbridge.com/en/news/295097600.md) - [zh-HK](https://longbridge.com/zh-HK/news/295097600.md) generator: "portal-rs" --- # Regenxbio | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 108.02 M Revenue: As of FY2026 Q2, the actual value is USD 108.02 M, beating the estimate of USD 96.46 M. EPS: As of FY2026 Q2, the actual value is USD 0.43, beating the estimate of USD 0.015. EBIT: As of FY2026 Q2, the actual value is USD 37.04 M. ### Cash Position REGENXBIO Inc.’s cash, cash equivalents, and marketable securities totaled $105.5 million as of June 30, 2026, a decrease from $240.9 million as of December 31, 2025. In July 2026, the company received over $200 million in new capital, including a $100 million milestone payment from AbbVie and approximately $108 million in net proceeds from a public offering. This resulted in a pro forma cash, cash equivalents, and marketable securities balance of approximately $313 million as of June 30, 2026, after accounting for the July 2026 receipts. ### Revenues Total revenues for the three months ended June 30, 2026, were $108.0 million, compared to $21.4 million for the same period in 2025. This increase was primarily due to a $100.0 million development milestone achieved in Q2 2026, partially offset by a - $16.7 million decrease in ZOLGENSMA® royalty revenues. License and royalty revenue increased to $103.841 million in Q2 2026 from $18.465 million in Q2 2025, while service revenue rose to $4.178 million from $2.894 million over the same periods. For the six months ended June 30, 2026, total revenues were $114.412 million, compared to $110.371 million for the six months ended June 30, 2025. ### Operating Expenses Research and Development (R&D) expenses decreased to $56.1 million for the three months ended June 30, 2026, from $59.5 million for the corresponding period in 2025. General and Administrative (G&A) expenses increased to $21.6 million for Q2 2026, up from $19.9 million in Q2 2025. Total operating expenses for Q2 2026 were $78.756 million, down from $84.637 million in Q2 2025. For the six months ended June 30, 2026, total operating expenses were $168.511 million, compared to $161.522 million for the six months ended June 30, 2025. ### Income (Loss) from Operations REGENXBIO Inc. reported income from operations of $29.263 million for the three months ended June 30, 2026, a significant improvement from a loss from operations of - $63.278 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the loss from operations was - $54.099 million, compared to a loss of - $51.151 million for the six months ended June 30, 2025. ### Net Income (Loss) Net income for the three months ended June 30, 2026, was $22.7 million, compared to a net loss of - $70.9 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the net loss was - $67.342 million, compared to a net loss of - $64.788 million for the six months ended June 30, 2025. ### Operational Metrics and Milestones REGENXBIO Inc. is on track to initiate a Biologics License Application (BLA) submission for RGX-202 for Duchenne muscular dystrophy in Q3 2026, with potential accelerated approval in the second half of 2027. The Phase III AFFINITY DUCHENNE® trial for RGX-202 met its primary endpoint with high statistical significance (p<0.0001). The company expects to announce topline data from pivotal subretinal wet AMD studies (ATMOSPHERE® and ASCENT®) for surabgene lomparvovec (ABBV-RGX-314) in Q4 2026, with global regulatory submissions anticipated in 2027. REGENXBIO Inc. also plans to resubmit the BLA for RGX-121 for Hunter syndrome in Q3 2026, following a positive Type A meeting with the FDA. ### Outlook / Guidance REGENXBIO Inc. expects its cash, cash equivalents, and marketable securities, including recent milestone payments and offering proceeds, to be sufficient to fund operations into Q4 2027. This guidance is based on current operational plans and excludes the impact of potential material payments from partners or licensees. It also does not account for any additional potential dilutive or non-dilutive funding opportunities. ### Related Stocks - [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md) ## Related News & Research - [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md) - [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md) - [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md) - [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md) - [Northrop Grumman announces R$ 0.17 per unit dividend for Q3 2026](https://longbridge.com/en/news/296645808.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**